WCN26-2982 IMPACT OF URINE cAMP/PLASMA ARGININE VASOPRESSIN RATIO ON RESPONSE TO TOLVAPTAN IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Read full text Summarise with VIRAT
Authors: Kota Kakeshita, Teruhiko Imamura, Tsutomu Koike, Yukine Senda, Shingo Yokoyama, Sayaka Murai, Ayako Shimizu, Hidenori Yamazaki, Koichiro Kinugawa
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The clinical feasibility and efficacy of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD) patients remains uncertain. In ADPKD, increased adenosine-3', 5'-cyclic monophosphate (cAMP) in the renal tubules causes growth of kidney cysts and progression of renal dysfunction. Tolvaptan, a vasopressin type-2 receptor antagonist, inhibits cAMP synthesis by blocking arginine vasopressin (AVP) stimulation in the renal collecting ducts. The level of urine cAMP relative to plasma AVP, which indicates the residual function of the renal collecting ducts in response to AVP stimulation, might be a key to predicting the therapeutic magnitude of tolvaptan in ADPKD patients.

Fields of Study & Subjects

Genetic and Kidney Cyst Diseases Electrolyte and hormonal disorders Ion Transport and Channel Regulation

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105727–105727
Publication date
25 March 2026
Language
EN